Harnessing immune effector cells to benefit cancer patients is becoming more and more
prevalent in recent years. However, the increasing number of different therapeutic …

Harnessing the immune-system to eradicate cancer is becoming a reality in recent years.
Engineered immune cells, such as chimeric antigen receptor (CAR) T cells, are facing the …

Adoptive transfer of T cells expressing a chimeric antigen receptor (CAR) is a promising cell-
based anticancer therapy. Although clinical studies of this approach show therapeutic …

Cancer immunotherapies are highly potent and are gaining wide clinical usage. However,
severe side effects require focusing effector immune cell activities on the tumor …

Simple Summary Chimeric antigen receptor (CAR) T cell therapy can be associated with
substantial side effects primarily due to intense immune activation following treatment, or …

Despite the success of CAR-T cell cancer immunotherapy, challenges in efficacy and safety
remain. Investigators have begun to enhance CAR-T cells with the expression of accessory …

In the recent decades, chimeric antigen receptor (CAR) therapy signaled a new
revolutionary approach to cancer treatment. This method seeks to engineer immune cells …

A recent study published in Cell by Lexus et al. presented CAR-T cell as a carrier that could
secrete extracellular vesicles (EVs) containing immunostimulatory RNA RN7SL1, which …

Chimeric antigen receptor (CAR) T-cell therapy engineers T-cells to express a synthetic
receptor which redirects effector function to the tumor, to improve efficacy and reduce …

Genetic engineering of cellular function holds much promise for the treatment of a variety of
diseases including gene deficiencies and cancer. However, engineering the full …